About

Entero Healthcare Solutions operates pharmacy retail, the organized channel within India's consumer discretionary sector. Consolidated quarterly revenue ₹1,500–1,900 Cr at 4% operating margins; smaller standalone segment consistently unprofitable. Market cap ₹6,162 Cr reflects 49x PE multiple.

Face value: ₹10

Market cap

₹7,311 Cr

P/E

58.3×

P/B

4.3×

Dividend yield

0%

ROE

6.7%

ROCE

12.5%

Debt / equity

0.34

OPM

4%

EPS (TTM)

₹28.8

Book value

₹388.1

52-week high

₹1,898.4

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

High PE ratio (49.14) suggests expensive valuation; verify if consolidated revenue growth (+23.5% YoY) and runway justify this multiple
Standalone segment persistently unprofitable (OPM -11.64% to -28.56% across all quarters), eroding group returns; clarify if this represents turnaround opportunity or structural drag
Consolidated OPM thin at 4.03%; verify whether pharmacy retail industry structurally operates at low margins or if Entero lags on cost efficiency
ROE 6.74% trails typical cost of capital; verify if this reflects capex-heavy growth phase or persistent margin constraints

Generated analysis · source review pending

Growth drivers

Consolidated quarterly revenue +23.5% YoY (Sep 2025: ₹1,570.95 Cr → Jun 2026: ₹1,940.5 Cr); verify if driven by store expansion or like-for-like growth
Standalone segment operational but unprofitable (OPM -11.64% to -28.56%); clarify strategic rationale and path to profitability
Pharmacy retail penetration in India expanding as organized retail gains ground; verify Entero's footprint growth and market share trends
Conservative leverage (D/E 0.34) enables capex; verify store-opening pipeline and return expectations

Generated analysis · source review pending

₹1,680.8+55.2%1Y

Beta

0.77

Damps index moves

Volatility (1y)

39.6%

Annualised, daily returns

RSI (14)

39.4

Neither overbought nor oversold

Rel. strength (1y)

43.3%

Ahead of the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Revenue CAGR of 25.9% over the last 3 years
+Outperformed the universe by 43.3% over 1 year

Cons

−Low return on equity of 5.3% (3-yr avg)
−Thin operating margin of 4%

Research score

Structured signal from quality, growth, valuation and momentum.

64/100

Business quality: 28
Growth: 100
Valuation: 28
Momentum

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MICROCAP 250 NIFTY TOTAL MARKET

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Lenskart Solutions LimitedLENSKARTLENSKART	₹1,20,170 Cr	₹1,20,390 Cr	₹9,634 Cr	₹2,005 Cr	19.9%	₹655 Cr	5.7%	8.6%	6.7%	19
Meesho LimitedMEESHOMEESHO	₹99,812 Cr	₹99,812 Cr	₹12,626 Cr	₹-1,485 Cr	-11.8%	₹-1,358 Cr	-10.8%	-23.8%	-31%	-40
Info Edge (India) LimitedNAUKRINAUKRI	₹77,808 Cr	₹77,808 Cr	₹3,375 Cr	₹1,249 Cr	35.7%	₹1,600 Cr	53.7%	4.9%	4%	-19
Swiggy LimitedSWIGGYSWIGGY	₹65,695 Cr	₹65,795 Cr	₹24,904 Cr	₹-2,927 Cr	-14%	₹-3,749 Cr	-18%	-24.6%	-19.7%	-16
Vishal Mega Mart LimitedVMMVMM	₹46,609 Cr	₹46,609 Cr	₹13,493 Cr	₹1,969 Cr	14.6%	₹892 Cr	6.5%	15.7%	12.1%	17
Urban Company LimitedURBANCOURBANCO	₹24,111 Cr	₹24,111 Cr	₹1,717 Cr	₹-311 Cr	-14.3%	₹-334 Cr	-15.1%	-6.3%	-11.9%	-115
Cartrade Tech LimitedCARTRADECARTRADE	₹13,472 Cr	₹13,472 Cr	₹807 Cr	₹276 Cr	33%	₹231 Cr	31.3%	11.9%	9.5%	21
Vedant Fashions LimitedMANYAVARMANYAVAR	₹12,617 Cr	₹12,617 Cr	₹1,345 Cr	₹652 Cr	48.1%	₹403 Cr	30.3%	30.4%	27.6%	198
Indiamart Intermesh LimitedINDIAMARTINDIAMART	₹9,738 Cr	₹9,738 Cr	₹1,611 Cr	₹543 Cr	33.8%	₹493 Cr	30.3%	22.9%	20.7%	-10
Brainbees Solutions LimitedFIRSTCRYFIRSTCRY	₹9,124 Cr	₹9,718 Cr	₹8,792 Cr	₹289 Cr	3.1%	₹-125 Cr	-2.4%	0.6%	-2.9%	81
Aditya Birla Lifestyle Brands LimitedABLBLABLBL	₹9,085 Cr	₹9,919 Cr	₹8,601 Cr	₹1,389 Cr	16%	₹176 Cr	2%	15.6%	23.3%	59
Medplus Health Services LimitedMEDPLUSMEDPLUS	₹7,858 Cr	₹7,858 Cr	₹7,229 Cr	₹610 Cr	8.8%	₹210 Cr	3.2%	13.1%	11.8%	79

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	3,300	3,922	5,096	6,591
COGS	3,032	3,570	4,609	5,911
Gross profit	268	352	486	680
	204	240	315	414
	64	112	172	266
OPM %	1.9%	2.9%	3.4%	4%
Depreciation	24	25	31	43
Interest	49	66	42	54
	6	14	40	11
Profit before tax	-4	36	139	179
Tax	7	-4	31	34
Tax %	201.1%	-11.9%	22.6%	18.7%
	-11	40	107	146
PAT margin %	-0.3%	1%	2.1%	2.2%
EPS (₹)	-0.2	10.8	21.8	26.4
EPS adjusted (₹)	-27	9	21.8	26.4
Annual report	—	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	4	4	43	44	44
Reserves	—	591	1,595	1,681	1,645
Minority interest	—	3	3	46	64
	—	374	276	299	567
	—	338	428	633	1,281
Total equity & liabilities	—	1,309	2,345	2,703	3,600
	112	268	289	559	861
CWIP	—	0	—	0	0
Investments	—	0	0	58	130
	—	1,041	2,056	2,086	2,610
Total assets	—	1,309	2,345	2,703	3,600

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-45	-37	-77	96
	-49	-705	220	-303
	73	863	-74	124
Net cash flow	-21	121	69	-83
Free cash flow	-51	-42	-88	29
CFO / Operating profit %	-70.8%	-32.7%	-44.8%	36.2%

Compounded sales growth

7 years: —
5 years: —
3 years: 26%
1 year: 29%

Compounded profit growth

7 years: —
5 years: —
3 years: —
1 year: 36%

Stock price CAGR

10 years: —
5 years: —
3 years: —
1 year: 52%

Return on equity

7 years: —

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	8.1%	9%	9.5%	10.3%
EBITDA margin %	1.9%	2.9%	3.4%	4%
EBIT margin %	1.2%	2.2%	2.8%	3.4%
PAT margin %	-0.3%	1%	2.1%	2.2%
Working capital
Receivable days	57	57	59	67
Inventory days	41	43	52	52
Payable days	25	24	31	45
NWC days	73	77	80	74
Leverage
Current ratio	1.64	3.34	2.46	1.58
Debt to EBITDA	5.84	2.46	1.74	2.13
Debt to equity	0.63	0.17	0.17	0.34
Interest coverage	0.9	1.5	4.3	4.4
Asset turnover	2.52	1.67	1.89	1.83
Return ratios
Return on assets %	-0.8%	1.7%	4%	4.1%
Return on capital employed %	6.6%	8.3%	10%	12.5%
Return on equity %	-1.9%	2.4%	6.2%	8.6%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	52.44%	52.44%	52.44%	52.44%	52.44%	52.42%	52.42%	52.42%	52.42%	52.42%	52.4%
	22.8%	23.3%	23.32%	23.82%	22.21%	19.92%	17.2%	14.67%	5.14%	4.03%	4.37%
	2.15%	2.28%	2.06%	7.73%	8.77%	9.64%	10.18%	9.65%	16.42%	16.62%	15.48%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	22.61%	21.98%	22.18%	16.01%	16.58%	18.02%	20.2%	23.26%	26.02%	26.93%	27.75%
No. of shareholders	—	—	—	—	—	—	—	36,334	40,333	39,084	39,709

Promoter holding down 0.04 percentage points since Dec 2023.

42 deals · 16 Feb 2024 – 18 Sept 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
18 Sept 2026	HDFC MUTUAL FUND	Bulk	NSE	Buy	13,90,000	₹1,695.00	₹235.61 Cr
18 Sept 2026	HDFC MUTUAL FUND	Block	NSE	Buy	13,90,000	₹1,695.00	₹235.61 Cr
18 Sept 2026	PRASID UNO FAMILY TRUST	Bulk	NSE	Sell	12,21,820	₹1,695.00	₹207.10 Cr
18 Sept 2026	PRASID UNO FAMILY TRUST	Block	NSE	Sell	12,21,820	₹1,695.00	₹207.10 Cr
18 Sept 2026	PRASID UNOFAMILY TRUST	Block	NSE	Sell	1,68,180	₹1,695.00	₹28.51 Cr
17 Sept 2026	PRASID UNO FAMILY TRUST	Bulk	NSE	Sell	4,10,000	₹1,692.98	₹69.41 Cr
17 Sept 2026	PRASID UNO FAMILY TRUST	Bulk	BSE	Sell	3,30,000	₹1,694.97	₹55.93 Cr
24 Aug 2026	PRASID UNO FAMILY TRUST	Bulk	BSE	Sell	10,88,500	₹1,377.80	₹149.97 Cr
24 Aug 2026	PRASID UNO FAMILY TRUST	Block	BSE	Sell	7,62,000	₹1,377.80	₹104.99 Cr
24 Aug 2026	3P INDIA EQUITY FUND 1	Bulk	BSE	Buy	7,62,000	₹1,377.80	₹104.99 Cr

1–10 of 42

1 / 5

Mr. VASUDEVAN SUJESHNon-Executive - Independent Director-Chairperson
Ms. SANDHYA GADKARI SHARMANon-Executive - Independent Director
Mr. RAJESH SHASHIKANT DALALNon-Executive - Independent Director
Mr. ARUN SADHANANDHAMNon-Executive - Nominee Director
Ms. SUMONA CHAKRABORTYNon-Executive - Nominee Director
Mr. PRABHAT AGRAWALExecutive Director-CEO-MD
Mr. PREM SETHIExecutive Director
Mr. Balakrishnan Natesan KaushikChief Financial Officer
Mrs. Sanu Vishal KapoorCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

12

across 4 fund houses

Held by these funds

4.03%

of the company's equity

All mutual funds

8.97%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

12 schemes · 4 fund houses

		Shares
Healthcare FundNEW	ICICI Prudential Mutual Fund	4.77 L	86.24	1.23%	1.095%	—
Flexi Cap Fund	Bank of India Mutual Fund	3.97 L	71.78	2.43%	0.912%	-0
Multi Cap FUND	Bank of India Mutual Fund	2.66 L	48.06	3.6%	0.61%	-0
SMALL CAP FUND	Bank of India Mutual Fund	2.06 L	37.26	1.13%	0.473%	-0
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	1.5 L	27.13	3.42%	0.345%	+38,330
Large & Mid Cap Fund	Bank of India Mutual Fund	86,166	15.6	2.95%	0.198%	-0
Consumption Fund	Bank of India Mutual Fund	82,356	14.91	4.03%	0.189%	-0
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	42,139	7.63	0.31%	0.097%	-923

1–8 of 12

1 / 2

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

30

Annual reports

3

Credit ratings

1

Affirmation of Credit Rating by India Ratings and Research4 Dec 2025 from India Ratings

Investor Presentation and earnings call

5

Aug 2026Transcript AI Summary PPT REC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results7 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

54 announcementsExport CSV

22 Sept 2026, 12:17 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

22 Sept 2026, 11:50 amInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

12 Sept 2026, 7:29 pmCompany Update

Entero Healthcare Solutions Limited Has Informed The Exchange About General Updates

General PDF

26 Aug 2026, 5:15 pmInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

24 Aug 2026, 7:58 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

24 Aug 2026, 7:38 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

19 Aug 2026, 7:15 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

19 Aug 2026, 7:12 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

Date	Category	Subject	Filing
22 Sept 2026, 12:17 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF
22 Sept 2026, 11:50 am	Insider Trading / SAST Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Loading announcements…

Entero Healthcare Solutions Limited

Entero Healthcare Solutions Limited

About

Key insights

Key risks

Growth drivers

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Board meetings1

Announcements

Board meetings1

Ratio timeline

Not in the F&O segment

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

1

1